Table 3.
Total number of tests received during 5 years of follow-up for prostate cancer patients on active surveillance
| Total tests received during 5 years of active surveillance | # (%) of all men n=1349 |
# (%) of low risk n=258 |
|---|---|---|
| Median PSA tests (IQR) | 11 (8) | 10 (5) |
| ≥5 PSA tests (every year) | 1222 (90.6%) | 242 (93.8%) |
| ≥10 PSA tests (every 6 mos for 5 years) | 798 (59.2%) | 152 (58.9%) |
| ≥20 PSA tests (every 3 mos for 5 years) | 138 (10.2%) | 18 (7.0%) |
| Median MRI (IQR) | 0 (0) | 0 (0) |
| ≥1 MRI | 167 (12.4%) | 31 (12.0%) |
| ≥2 MRI | 48 (4.7%) | 31 (12.0%) |
| ≥3 MRI | 48 (4.7%) | 11 (4.3%) |
| Median biopsies after diagnosis* | 1 (1) | 1 (1) |
| ≥2 biopsies after diagnosis* | 458 (34.0%) | 119 (46.1%) |
| ≥3 biopsies after diagnosis* | 196 (14.5%) | 53 (20.5%) |
| ≥4 biopsies after diagnosis* | 89 (6.6%) | 27 (10.5%) |
| Combo: ≥10 PSA tests and ≥2 biopsies | 296 (21.9%) | 83 (32.2%) |
| Combo (Prostate Cancer Research International Active Surveillance study 8): ≥14 PSA and ≥2 biopsies | 150 (11.1%) | 34 (13.2%) |
| Combo (Hopkins14): ≥10 PSA tests and ≥4 biopsies | 68 (5.0%) | 23 (8.9%) |
*
All men were required to have one biopsy within 2 years after diagnosis for inclusion in the study, so 2 biopsies means 1 additional biopsy beyond the necessary biopsy for inclusion to the cohort. These categories are not mutually exclusive (i.e. men who had ≥4 biopsies after diagnosis are also counted as having ≥3 and ≥2 biopsies.